M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Imatinib Mesylate (Gleevec)

First Posted Date: 2007-07-12

Last Posted Date: 2011-08-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00500188

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Pain Management Following TRAM Flap for Breast Reconstruction

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Saline
Drug: Bupivicaine

First Posted Date: 2007-07-12

Last Posted Date: 2013-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00500565

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Extraperitoneal Lymph Node Dissection in Patients With Cervical Cancer

Completed

Conditions: Cervical Cancer

Interventions: Procedure: Extraperitoneal Laparoscopic Lymphadenectomy

First Posted Date: 2007-07-12

Last Posted Date: 2012-03-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00500435

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lyndon Baines Johnson General Hospital, Houston, Texas, United States

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Phase 3

Terminated

Conditions: Leukemia
Lymphoma

Interventions: Drug: Insulin Glargine
Drug: Insulin Aspart

First Posted Date: 2007-07-12

Last Posted Date: 2015-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT00500240

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Imatinib Mesylate
Drug: Leuprolide
Drug: Goserelin Acetate

First Posted Date: 2007-07-12

Last Posted Date: 2015-04-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00500110

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Prevalence of Endometrial Abnormalities In Obese Women

Conditions: Obesity

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-07-12

Last Posted Date: 2021-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT00500591

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: RAD001

First Posted Date: 2007-07-11

Last Posted Date: 2016-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT00499603

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging

Terminated

Conditions: Advanced Cancers

Interventions: Procedure: Nuclear Medicine Cardiac Scan
Procedure: PET/CT Cardiac Scan

First Posted Date: 2007-07-11

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00499382

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Etoposide
Drug: G-CSF
Drug: GM-CSF
Drug: Isophosphamide
Drug: Rituximab
Procedure: Apheresis

First Posted Date: 2007-07-11

Last Posted Date: 2013-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT00499343

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy

Completed

Conditions: Prostate Cancer

Interventions: Procedure: Computed Tomography (CT) Scan

First Posted Date: 2007-07-11

Last Posted Date: 2023-03-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00499421

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy